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Multiple endocrine neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a
rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although geno-
type–phenotype studies have so far failed to identify any statistical correlations, some families harbor recur-
rent tumor patterns. The function of MENIN is unclear, but has been described through the discovery of its
interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to
directly alter its regulation abilities. We report on a cohort of MEN1 patients from the Groupe d’e´tude des
Tumeurs Endocrines. Patients with a molecular diagnosis and a clinical follow-up, totaling 262 families
and 806 patients, were included. Associations between mutation type, location or interacting factors of the
MENIN protein and death as well as the occurrence of MEN1-related tumors were tested using a frailty Cox
model to adjust for potential heterogeneity across families. Accounting for the heterogeneity across families,
the overall risk of death was significantly higher when mutations affected the JunD interacting domain
(adjusted HR 5 1.88: 95%-CI 5 1.15–3.07). Patients had a higher risk of death from cancers of the MEN1 spec-
trum (HR 5 2.34; 95%-CI 5 1.23–4.43). This genotype–phenotype correlation study confirmed the lack of
direct genotype–phenotype correlations. However, patients with mutations affecting the JunD interacting
domain had a higher risk of death secondary to a MEN1 tumor and should thus be considered for surgical
indications, genetic counseling and follow-up.
INTRODUCTION
Multiple endocrine neoplasia syndrome type 1 (MEN1, OMIM
131100) is an autosomal dominant disorder that predisposes car-
riers to endocrine tumors (1). The prevalence has been estimated
between 1 out of 30 000 and 1 out of 100 000 (2). The tumors
mainly develop from endocrine tissues and may arise from para-
thyroid glands (90–100%), the pancreas (50–70%), pituitary
gland (20–40%), adrenal glands (20–40%) and at a lower fre-
quency from the bronchi and thymus (,10%) (3). MEN1 syn-
drome is secondary to germline mutations of the MEN1 gene,
mapped to the 11q13 locus and encoding for the MENIN
protein (4). The function of the MENIN protein remains
unclear. Two types of functional domains are described:
Nuclear localization sequences (NLS) and the MENIN
domain (5,6). No mutational hot spots have been defined, and
all the protein domains are affected (7–9). In contrast with
other genetic diseases, no obvious genotype–phenotype corre-
lations have been established so far (10,11). The existence of fa-
milial clusters of thymic tumors raised the issue of possible
heterogeneity across families. Mild/late MEN1 phenotypes
exist, as well as family phenotypes with prominent features of
prolactinomas, of isolated hyperparathyroidism or with more
aggressive gastro-pancreatic neuroendocrine tumors (NETs)
(12). The severity of the disease is at present unpredictable











(13). Pancreatic tumors and thymic tumors may unfortunately
turn into aggressive tumors with metastatic spread (4,14,15).
Nevertheless, nobody knows whether the severity of such
tumors might be related to specific mutations or not. Gender
has been shown to be a significant modifying factor for
disease expressivity. Indeed, we previously showed that
women were more prone to pituitary lesions and males to gastri-
nomas (16–19). Thymic tumors were thought to occur almost
exclusively in men in many studies (20,21). Nevertheless, a
recent large Japanese collection of MEN1 data did not confirm
what used to be considered a general rule (22).
Previous phenotype–genotype correlation studies on smaller
population samples have been published (2,7,23). The largest
study published to date counted 258 patients (23). Such studies
require larger numbers of patients because of the various types
of mutations. In addition, MEN1 exhibits a high, but progressive
penetrance during the lifespan. Therefore, correlation studies
need to take into account the time-dependent expressivity and
expected heterogeneity across families using appropriate statis-
tical techniques (10). Finally, MENIN interacts with various part-
ners (9,24). Mutations affecting the interacting domain of MEN1
could interfere with and abolish interactions with functional part-
ners (Fig. 1) (24–28). Loss of interaction (LOI) with MENIN may
modify disease expressivity (28). Various functions such as (i)
regulation of transcription with JunD, MLL-HMT and others,
(ii) stabilization of the double DNA strand and of the genome
and (iii) regulation of cell cycle and division (9) have been
described for each partner. Therefore, the absence of physiologic
interactions also needs to be evaluated in a MEN1 genotype–
phenotype study.
This study aimed to assess associations between the pheno-
typic manifestation of the disease and both the mutation types
and the locations in interacting domains. This MEN1 geno-
type–phenotype study was based on a cohort of 806 patients
from 262 unrelated families with molecular diagnosis collected
through the ‘Groupe d’e´tude des Tumeurs Endocrines (GTE)’.
RESULTS
Overall, 262 mutations were diagnosed in the 806 patients.
Among these, 463 patients (59%) carried a truncating mutation
and 142 (18%) a non-truncating mutation (Table 1). The gender
ratio (female/male) was 1:1. Median follow-up was 47 years
(Inter-quartile ratio ¼ 30–59 years; ranging from 3 to 86
years). Seventy-five patients were under 18 years old (9%),
and at their last follow-up, a total of 118 patients (15%) had
not had a tumor diagnosed. Overall, 1522 tumors were diag-
nosed (1.9 tumors per patient). The heterogeneity across fam-
ilies was statistically significant in 77% of cases (65 out of 84
tests) (Supplementary Material, Fig. S1) and followed a log
normal distribution (Fig. 2). Thus, subsequent estimates of
genotype–phenotype association accounted for this heterogen-
eity across families. No mutational hot spot was evidenced.
There was no statistically significant association between the
genotypic criteria ‘truncating or non-truncating mutation’ and
the phenotypic criteria. As well, no statistically significant asso-
ciation was found between the genotypic criteria ‘5′ versus 3′
mutation’ and the different phenotypic criteria. In contrast,
five tests related to the LOI of MENIN with its partner were stat-
istically significant before correction (Table 2). After correc-
tion, only JunD-LOI remained significantly associated with an
increased overall risk of death (P-value ¼ 0.008; Q-value ¼
0.048). Gender was significantly associated with the occurrence
of pituitary tumors in females (Q-value , 1024) and thymic
tumors in males (Q-value ¼ 0.010). A higher risk of death was
observed for men than for women (Q-value ¼ 1024). Patients
with JunD-LOI had a higher risk of MEN1-related death after
adjustment for gender [HR ¼ 1.99 (CI-95% ¼ (1.08; 3.63))]
(Table 3). More precisely, JunD-LOI was associated with
decreased survival in the subgroup of patients who died from
MEN1-related tumors [HR ¼ 2.34 (CI-95% (1.23; 4.43))]
(Table 3 and Fig. 3). Conversely, JunD-LOI was not associated
with either deaths related to MEN1 non-cancer etiologies (P ¼
0.690), or with non-MEN1-related deaths (P ¼ 0.920). After ex-
cluding the 23 patients with thymic tumors, patients with
JunD-LOI still presented a higher risk of death [HR ¼ 1.73
(CI-95% (1.03; 2.93)); P ¼ 0.020].
DISCUSSION
So far, no direct correlation between genotype and phenotype
has been established in MEN1 disease (12). This new
Figure 1. Schematic representation of the genomic organization of the MEN1 gene. The human MEN1 gene consists of 10 exons that span more than 9 kb of
genomic DNA and encodes a 610 amino acid protein. The start (ATG) and stop (TGA) codons in exons 2 and 10, respectively, are indicated. Exon 1, the 5′ part
of exon 2, and the 3′ part of exon 10 are untranslated (indicated by open boxes). (A) 5′ and 3′ segmentation of the gene product distinguishes two equivalent parts
from exons 2 and 3 versus exons 8–10, respectively. (B) The distribution of mutation types is represented showing truncating mutations (black boxes) and non-
truncating mutations (open boxes). (C) The MENIN interacting partners are positioned (adapted from 9).











phenotype–genotype correlation study reports on the largest
cohort of MEN1 patients to date. This study used a
time-to-event statistical analysis and considered for the first
time the effect of mutations located in the interacting
domains. Accounting for the heterogeneity across families,
mutations affecting the interacting domain with JunD were
associated with a significantly higher risk of death secondary
to MEN1-related cancers.
The MEN1 GTE cohort has already been described and is
deemed representative of MEN1 disease in Western Europe
(17–20,29–31) with no major difference in terms of lesion
prevalence when compared with the independent German
cohort (23). The GTE cohort had a median follow-up observa-
tion time of 47 years and thus allowed to study reliably the
age-dependent expressivity of MEN1 disease with time-
to-event techniques (17–20,29–33). The time-to-event
approach has already been used once on a limited patient
sample and without considering the potential heterogeneity
across families (23).
Testing the statistical independence of the observations
within families (i.e. the heterogeneity across families) was a
prerequisite for the subsequent analyses. Indeed, significant
heterogeneities were identified for most tumors as well as
for survival and led us to account for this inter-familial vari-
ability. However, a positive test could not identify a family
particularly at risk of developing a given lesion. Such results
require further studies and raise the issue of allelic modifying
factors of the MENIN protein that may explain the variable
penetrance and expressivity of the disease.
In addition, we also used a false discovery rate (FDR) cor-
rection procedure (34) to account for multiple testing. The
Benjamini and Hochberg method was chosen for its ability
to control the FDR while staying adequate in case of
independence between tests and when a positive dependency
of the tests could be hypothesized (35,36). Indeed, a signifi-
cant genotype–phenotype association does not generally
provide any information about the effects of other distinct gen-
otypes. In case of overlapping interacting domains, similar
results would be expected for the genotype–phenotype asso-
ciations leading to a positive dependency between tests.
Using an appropriate methodology in the largest cohort of
MEN1 patients with confirmed mutations, we (i) analyzed
the impact of mutations located in the interacting domain
resulting in a putative LOI while accounting for heterogeneity
across families and (ii) we conducted a survival study consid-
ering death as a phenotypic aspect of the disease.
Regarding the phenotypic expression of the six tested tumor
types, no genotypic correlation was found. This was in accord-
ance with previous results from the literature (23) (Table 4).
As already pointed out by the GTE, an association was
found between gender and phenotypic criteria such as the de-
velopment of pituitary tumors, thymic tumors (19) and sur-
vival (21). The prevalence of pituitary adenomas is greater
in female MEN1 patients than in the non-MEN1 population.
Thymic tumors are known to occur almost exclusively in
male patients, at least in Western Europe and the USA
(21,37). These gender-related differences were taken into
account in the adjustment computations.
The function of the MENIN protein was ascertained by
various approaches, one of which was the identification of
MENIN partners. When the transcription factor JunD is
deprived of MENIN, it switches from growth suppressor to
growth promoter (26). The hypothesis that point mutations
could affect the interaction with known functional partners
was supported by structural or functional data available for
some of MENIN partners such as MLL, JunD and others
Table 1. Descriptive statistics of the GTE cohort
Phenotypic criteria
Tumor type Death
Parathyroid Pituitary Adrenal Pancreatic Bronchial Thymic
Total (n ¼ 806) 645 260 145 415 34 23 93
Gender
Men (n ¼ 373 out of 806) 292 (46%) 93 (36%) 69 (48%) 198 (47.7%) 16 (47%) 22 (96%) 59 (63%)
Women (n ¼ 433 out of 06) 353 (54%) 167 (65%) 76 (52%) 217 (52.3%) 18 (53%) 1 (4%) 34 (37%)
Genotypic criteria Mutation typea
Truncating (n ¼ 473 out of 806) 374 (58%) 135 (52%) 89 (61%) 243 (59%) 14 (42%) 12 (52%) 52 (56%)
Non-truncating (n ¼ 142 out of 806) 109 (17%) 42 (16%) 26 (18%) 73 (17%) 9 (26%) 3 (13%) 17 (18%)
Other (n ¼ 191 out of 806) 162 (25%) 83 (32%) 30 (21%) 99 (24%) 11 (32%) 8 (35%) 24 (26%)
Mutation localizationb
5′ (n ¼ 178 out of 623) 142 (43%) 61 (33%) 27 (23%) 95 (30%) 7 (29%) 6 (37%) 17 (24%)
3′ (n ¼ 322 out of 623) 251 (57%) 90 (50%) 55 (47%) 163 (51%) 15 (62%) 8 (50%) 43 (62%)
Interaction domainb
JunD (n ¼ 298 out of 800) 251 (39%) 103 (40%) 91 (64%) 163 (40%) 12 (36%) 15 (65%) 46 (50%)
NF-kB (n ¼ 116 out of 786) 95 (15%) 35 (14%) 19 (14%) 52 (13%) 5 (15%) 4 (18%) 12 (13%)
Smad3 (n ¼ 479 out of 800) 392 (61%) 155 (60%) 82 (57%) 239 (58%) 12 (36%) 13 (56%) 50 (54%)
RPA2 (n ¼ 247 out of 800) 203 (32%) 78 (30%) 43 (30%) 133 (32%) 12 (36%) 8 (35%) 30 (32%)
NMHC II-A (n ¼ 219 out of 788) 182 (29%) 71 (31%) 37 (27%) 109 (27%) 4 (12%) 8 (35%) 26 (28%)
FANCD2 (n ¼ 219 out of 788) 178 (28%) 67 (27%) 42 (30%) 106 (26%) 7 (21%) 5 (23%) 20 (22%)
HDAC1 (n ¼ 403 out of 800) 328 (51%) 137 (53%) 75 (52%) 210 (51%) 12 (36%) 15 (65%) 48 (52%)
CHES1 (n ¼ 304 out of 786) 242 (39%) 92 (37%) 49 (35%) 141 (35%) 12 (36%) 8 (35%) 36 (39%)
NLS (n ¼ 89 out of 786) 77 (12%) 32 (13%) 11 (8%) 39 (10%) 3 (9%) 3 (14%) 9 (10%)
aTruncating ¼ FS+NS; Non-truncating ¼ IF+MS; Other ¼ SP+other.
bDifference in the total number of patients (n ¼ 806) is due to missing values. Tumor types considered were the most frequent ones.











(24,38,39). We generalized this hypothesis to all the factors
with known interaction domains because in vitro and in vivo
models demonstrated that some MENIN mutations affected
the functions of MENIN protein with regard to its partners
(25). Functional studies on cancer cells revealed that the
MENIN protein played a crucial role in repressing the tran-
scription of pro-oncogenic factors such as JunD or MLL
(28,39). The MLL protein was a promising interacting factor
of MENIN. Unfortunately, the MLL interacting domain with
MENIN was not published as a primary amino acid sequence
and was, thus, not included as a genotypic factor, but its three-
dimensional model suggests the existence of an interacting
domain binding the MENIN protein similar to that for JunD
(38,39).
When mutated, the JunD interacting domain was associated
with a significant decrease in overall survival. This result is of
interest because of the already known pro-oncogenic functions
of JunD in various cancer types (40,41). MENIN protein
lowers the transcriptional activity when binding to JunD in tar-
geted tissues, with secretory and non-secretory consequences
(24,42–44). In this cohort, survival was significantly lower
among patients carrying mutations affecting the JunD interact-
ing domain, with a 2-fold increased risk of dying from MEN1-
related cancers. JunD-LOI mutations were not associated with
either other causes of death or with any peculiar phenotypic
expressivity. This aggressiveness was not only related to
thymic tumors because the risk of dying remained significant
after their removal from the computations. Nonetheless,
JunD is not the only factor to bind in this region, and
MLL-LOI might be implicated in tumor aggressiveness
when such mutations are diagnosed. The conclusion drawn
from this work is that a mutation located in the area involved
in JunD interactions may decrease survival in MEN1-related
tumors. To confirm this hypothesis, functional studies measur-
ing JunD or MLL activity should be conducted in patients with
a mutation located in the codon position 1–40, 139–242 and
323–428. Although the underlying mechanisms remain
unclear, the identification of a group of at-risk mutations in
the MEN1 gene is relevant in terms of clinical implications
for counseling, follow-up rules and surgical indications.
In the GTE cohort, half of the MEN1-cancer-related deaths
were due to pancreatic NETs. The indication for surgery in
pancreatic NET is difficult because several factors need to
be considered. These include: the size of the largest tumor
(2 cm or more) (24), the ability to control hormonal secretions,
the progression of the tumor, a high mitotic index in the diag-
nostic biopsy, the physiologic status of the patient and the
patient’s motivation for surgery (SFNGE guidelines) (33).
When there are doubts about the usefulness of surgery, the
JunD-LOI status may be an important additional element for
decision making. International guidelines advise a regular
Figure 2. P–P plot for P-values of the heterogeneity tests across families in this study (GTE cohort-n ¼ 806, 84 heterogeneity tests). Observed P-values ap-
proximately display a log-normal distribution for the 84 heterogeneity tests in this study.
Table 2. Genotype–phenotype correlations using the frailty model of Cox-
hazard ratio and FDR correction in the GTE cohort–n ¼ 806–2011
Phenotype Genotype HR (95% CI) P-values FDR
correction
(Q-value)
Death JunD-LOI 1.88 (1.15; 3.07) 0.008∗ 0.048∗∗
Bronchial tumor Smad3-LOI 0.37 (0.18; 0.78) 0.009∗ 0.1
Thymic tumor JunD-LOI 3.01 (1.15; 7.86) 0.024∗ 0.14
Pancreatic tumor CHES1-LOI 0.78 (0.61; 0.99) 0.04∗ 0.54
Bronchial tumor NMHC-LOI 0.33 (0.11; 1.003) 0.05 0.3
Twelve genotype criteria correlated with 7 phenotypic criteria. The five most
significant results are shown, without (P-values) and with the FDR correction
(Q-value). Significant tests are shown without (∗) and with the FDR correction
procedure (∗∗). Further results in the text are corrected Q-value values.











abdominal imaging follow-up every 3–5 years. We would rec-
ommend a reinforced follow-up program in patients who are
genetically at risk because of a JunD-LOI mutation.
In conclusion, this study demonstrates the existence of
at-risk mutations within the codons involved in the interaction
between MENIN and JunD. In this study, JunD-LOI was sig-
nificantly associated with a higher risk of death. This reduced
survival was secondary to pleiotropic MEN1 cancers, suggest-
ing that the tumors are more aggressive. Specific recommen-
dations for pancreatic surgery and follow-up might be
pertinent in patients carrying a JunD-LOI mutation. The exist-
ence of an heterogeneity across families in MEN1 syndrome is
now established, suggesting the importance of genetic modify-
ing factors in the variable expressivity of MEN1 syndrome.
Further studies on the modifying factors implicated in hetero-
geneity across families of MEN1 syndrome might be a key to
understand the variable expressivity of MEN1 syndrome.
POPULATION AND METHODS
Population
The GTE network for MEN1, created in February 1991, brings
together clinical centers in France and Belgium together with
the four genetics laboratories in charge of diagnosis. In 2011,
the GTE cohort for MEN1 included a total of 912 patients
from 278 regularly followed families (17–20,29–31). To be
included in this genotype–phenotype correlation study,
Figure 3. Survival analysis in the GTE cohort, considering the JunD-LOI status and cause of death. Abscises represent the age at the event or at last follow-up.
Ordinates represent the probability of tumor occurrence (percentage). (A) Overall survival was significantly correlated with JunD-LOI. Three groups were
created: (B) risk of death from a MEN1 cause, (C) risk of death from a MEN1 cancer and (D) risk of death from a non-MEN1 cancer. Significant results
are highlighted on the plots. Patients of the GTE cohort were significantly more likely to die from MEN1 cancer than from any other cause.
Table 3. Impact of JunD-LOI on the risk of death (frailty Cox proportional model) in the GTE cohort–n ¼ 806–2011
Unadjusted HR Adjusted on gender HR
Association between JunD-LOI and causes of death
[number of patients (%)]
JunD-LOI 298
(37.3%)
HR (95% CI) P-value HR (95% CI) P-value
MEN1-related death (cancer or other complications) 34 (11%) 2.07 (1.13; 3.78) 0.01 1.99 (1.08; 3.63) 0.01
MEN1-non-cancer related death (secretion complications) 4 (1%) 0.82 (0.24; 2.83) 0.7 0.81 (0.23; 2.80) 0.7
All cancers related death (MEN1 or others) 34 (11%) 2.07 (1.18; 3.79) 0.008 2.04 (1.16; 3.60) 0.01
MEN1-cancer-related death 30 (10%) 2.42 (1.27; 4.61) 0.005 2.34 (1.23; 4.43) 0.006
Thymic tumor-related death 9 (3%) 2.94 (0.81; 10.67) 0.08 2.56 (0.71; 9.18) 0.15
Non-MEN1 cancer death 4 (1%) 0.94 (0.27; 3.20) 0.9 0.94 (0.27; 3.22) 0.9
Among the 93 patients who died during follow-up, 46 patients were diagnosed with a JunD-LOI (50%). The cause of death was missing for six patients. The 800
patients are compared with the causes of death of the 93 patients depending on their JunD-LOI status.











symptomatic or non-symptomatic MEN1 patients needed a
genetic MEN1 diagnosis and available data on phenotypic ex-
pression. Overall, 823 patients had a genetic diagnosis. Among
these, 17 patients (2.1%) from 16 different families were
excluded from the analysis because of missing information.
The analysis finally included 806 patients from 262 families
(Table 1).
Genotypic factors
The various genotypic abnormalities were grouped according
to the following classifications: (i) depending on the functional
aspect of MENIN: truncating (nonsense, frame-shift muta-
tions) versus non-truncating mutations (missense, in-frame
insertions or deletions) and versus the remaining mutations
(splicing and intronic mutations, intragenic and genic rearran-
gements), (ii) mutations in 5′ versus 3′: the 610 amino acids of
the MEN1 coding sequence were divided into 3 parts; the 5′
and 3′ parts encoded, respectively, by exons 2 and 3 and 8–
10 were considered and (iii) mutations affecting an interacting
domain, causing a LOI with the functional partners. Mapping
of the interacting domains has already been published and
reviewed (9). The following functional or interacting
domains were considered [protein name (codon positions)]:
JunD (1–40, 139–242 and 323–428), NF-kB (305–381),
Smad3 (40–278 and 477–610), Pem (278–476), NM23H1
(1–486), RPA2 (1–40 and 286–448), NMHC II-A (154–
306), FANCD2 (219–395), mSin3A (371–387), HDAC1
(145–450), ASK (558–610), CHES1 (428–610) and NLS
(479–497, 546–572 and 588–608) (Fig. 1). When the loca-
tions of mutations were compared, analyses were performed
with all types of mutations. For further analyses, the causes
of death were categorized as: (i) secondary to a cancer of
the MEN1 spectrum (i.e. involving the pancreas, parathyroid
glands, pituitary gland, adrenal glands, bronchi and thymus),
(ii) secondary to a non-MEN1-spectrum cancer and (iii) not
secondary to cancer (Table 5).
Statistical methods
Time-to-event techniques were used to identify genotype–
phenotype correlations. Events of interest were: (i) death
from any cause and (ii) first occurrence of each of the six
main types of MEN1 lesions (i.e. involving the pancreas, para-
thyroid glands, pituitary gland, adrenal glands, bronchi and
thymus). Events with fewer than 10 occurrences in the
cohort were excluded (stomach and brain). Birth was consid-
ered the baseline. Patients who did not experience an event
of interest during their follow-up were censored at the date
of their last follow-up. For each genotype–phenotype correl-
ation, a frailty Cox’s proportional hazards model was used
with the family as a frailty component (45). This model tests
for both heterogeneity across families (likelihood ratio test)
and genotype–phenotype associations and can be adjusted
for other covariates when necessary. The prognostic role of
the 12 genotypic profiles for each of the 7 phenotypic criteria
Table 5. JunD status of the 51 patients with a MEN1 cancer-related death in







Non-secreting pancreatic NET 14 7 7
Secreting pancreatic NET 12 8 4
Gastrinoma 8 5 3
Glucagonoma 2 1 1
Insulinoma 1 1 0
Vipoma 1 1 0
Thymic tumor 11 8 3
Bronchial NET 6 2 4
Ependymoma 2 2 0
Adrenal tumor 2 1 1
Pituitary adenoma 1 1 0
Gastric NET 1 0 1
Unknown origin 2 1 1
NET, neuro endocrine tumor.
Table 4. Previous genotype–phenotype studies in MEN1 syndrome
Study Sample size Phenotypic criteria Genotypic criteria Statistical analysis
Total Kindred Limits Advantages
Kouvaraki et al. (2) 109 24 5 tumor typesa
6 PET subtypes




Age not taken into account
No correction procedure
Direct comparisons (Fisher’s
exact test and x2)
Wautot et al. (7) 170 170 Familial tumor accumulation Grouped mutation typesc Age not taken into account Direct comparisons (x test)
Machens et al. (23) 258 116 5 tumor typesa
Age at tumor diagnosis
Malignancy





Meyer analysis (log rank test)
Present study 806 262 5 tumor typesa










Three genotype–phenotype studies were available in the literature, with various approaches.
aPET, pancreatic endocrine tumors, parathyroid, pituitary, adrenal and carcinoid (bronchial and thymic) tumors.
bReferring to exons 2, 9, 10 and others.
cReferring to truncating, non-truncating and other mutations.











(survival in addition to 6 types of tumor) was assessed using a
univariate frailty model. This analysis led to 84 genotype–
phenotype association tests (84 ¼ 12 × 7). To control the
risk of false positive results due to the multiplicity of tests,
the Benjamini and Hochberg FDR method was used (34–
36). The FDR is defined as the expected proportion of false
positives among all (significant) discoveries. Thus, for each
association test, we calculated a Q-value representing the
minimum FDR at which the statistical test may be considered
as a true positive (i.e. significant taking into account the multi-
plicity of tests) (46). A result was deemed false positive when
the corresponding Q-value was above 0.05. In addition, the
heterogeneity across families was assessed for each of these
tests, and a descriptive analysis was performed through a P–
P plot (Fig. 2). The association tests were also adjusted on
gender for phenotypic criteria when gender was thought to
be a confounding factor. In addition, interactions between
gender and other genotypic profiles were systematically
checked. Cumulative probabilities of lesion occurrence or
death were estimated using the Breslow estimator. Stata soft-
ware version 11 (Stata Corp., College Station, USA) was used
for frailty models and probability estimates, and SAS software
version 9.3 (SAS institute, Cary, USA) was used for all other
analyses.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
Many thanks to P. Bastable for the English revision of the manu-
script and A. Costa for the data administration of the Groupe
d’e´tude des Tumeurs Endocrines register on MEN1. The
authors also would like to thank the members of the GTE:
C. Ajzenberg; J.J. Altman; T. Aparicio; J.R. Attali; C. Badet;
J. Barbier; M. Barthet; B. Bauduceau; H. Becheur;
P. Bernades; X. Bertagna; J. Bertherat; O. Ble´try; P. Boissel;
J.M. Boyaval; L. Bresler; J.F. Bretagne; J. Bringer;
H. Brixi-Benmansour; L. Brunaud; J. Burger; G. Cadiot;
P. Carenco; B. Carnaille; B. Cathebras; M. Celerier;
R. Cohen; G. Chabrier; D. Chadenas; P. Chaffanjon;
D. Charitanski; J.A. Chayvialle; C. Colmar Montiel; J.M.
Comas; B. Conte Devolx; A. Cortot; E. Cosson; P. Cougard;
P. Cubertafond; P. D’Anella; P. Darsy; T. Defechereux;
F. Delecourt; J. Denis; C. Derrien; D. Dewailly; A.S. Dramais;
C. Droumaguet; C. Dubost; B. Emperauger-Beauvais; P. Emy;
S. Gauthier; A.P. Gimenez Roqueplo; D. Goldfain;
M. Gosselin; F. Grunenberger; A.M. Guedj; P.J. Guillausseau;
P. Hamon; J.F. Henry; P.J. Jaquet; C. Jublanc;
B. Knebelmann; J.L. Kraimps; A. Krivtzky; Lagarde F.; J.D.
Lalau; J.J. Legros; D. Levoir; N. Le´vy-Bohbot; Lips C.J.;
B. Maizeray-Cailliau; D. Malet; M. Malinski; G. Mantion;
Maroy B.; C. Mathe; M. Mathonnet; D. Melliere;
F. Me´ne´gaux; E.H. Metman; M. Meurisse; R. Modigliani;
M. Monsaingeon; C. Naouri; C. Oliver; F. Olivier; J. Orgiazzi;
L. Osmak; M. Parneix; C. Partenski; F. Pattou; J.L. Peix;
A. Pradignac; C. Pouget; M. Pugeat; M.L. Raffin-Sanson;
M. Rodier; P. Roger; P. Rougier; H. Rousset; J. Roy;
E. Sarfati; J.L. Schlienger; M. Schlumberger; P. Selvais;
P. Seve; D. Simon; I. Sobhani; O. Soubrane; J.C. Soule;
P. Thieblot; C. Thivolet; P. Thomopoulos; P. Valensi; M.C.
Vantighem; M.F. Verger; O. Verier-Mine; E. Verlet;
M. Veyrac; B. Vialettes; R. Viard, S. Walter; A. Warnet;
B. Wechsler; J.L. Wemeau; B. Woehl-Kremer; J. Young; Asso-
ciation Franc¸aise de Chirurgie Endocrinienne (AFCE)
members.
Conflict of Interest statement. None declared.
FUNDING
This work was supported by a grant from the University Hos-
pital of Dijon and the Regional council of Burgundy by the
Regional action plan for the innovation 2011.
REFERENCES
1. Wermer, P. (1968) Duality of pancreatogenous peptic ulcer.
N. Engl. J. Med., 278, 397–398.
2. Kouvaraki, M.A., Lee, J.E., Shapiro, S.E., Gagel, R.F., Sherman, S.I.,
Sellin, R.V., Cote, G.J. and Evans, D.B. (2002) Genotype-phenotype
analysis in multiple endocrine neoplasia type 1. Arch. Surg., 137,
641–647.
3. Brandi, M.L. (2000) Multiple endocrine neoplasia type 1. Rev. Endocr.
Metab. Disord., 1, 275–282.
4. Teh, B.T., McArdle, J., Chan, S.P., Menon, J., Hartley, L., Pullan, P., Ho,
J., Khir, A., Wilkinson, S., Larsson, C. et al. (1997) Clinicopathologic
studies of thymic carcinoids in multiple endocrine neoplasia type 1.
Medicine (Baltimore), 76, 21–29.
5. Guru, S.C., Manickam, P., Crabtree, J.S., Olufemi, S.E., Agarwal, S.K.
and Debelenko, L.V. (1998) Identification and characterization of the
multiple endocrine neoplasia type 1 (MEN1) gene. J. Intern. Med., 243,
433–439.
6. Guru, S.C., Goldsmith, P.K., Burns, A.L., Marx, S.J., Spiegel, A.M.,
Collins, F.S. and Chandrasekharappa, S.C. (1998) Menin, the product of
the MEN1 gene, is a nuclear protein. Proc. Natl. Acad. Sci. USA, 95,
1630–1634.
7. Wautot, V., Vercherat, C., Lespinasse, J., Chambe, B., Lenoir, G.M.,
Zhang, C.X., Porchet, N., Cordier, M., Beroud, C. and Calender, A. (2002)
Germline mutation profile of MEN1 in multiple endocrine neoplasia type
1: search for correlation between phenotype and the functional domains of
the MEN1 protein. Hum. Mutat., 20, 35–47.
8. Chandrasekharappa, S.C. and Teh, B.T. (2001) Clinical and molecular
aspects of multiple endocrine neoplasia type 1. Front. Horm. Res., 28,
50–80.
9. Lemos, M.C. and Thakker, R.V. (2008) Multiple endocrine neoplasia type
1 (MEN1): analysis of 1336 mutations reported in the first decade
following identification of the gene. Hum. Mutat., 29, 22–32.
10. Faivre, L., Collod-Beroud, G., Loeys, B.L., Child, A., Binquet, C.,
Gautier, E., Callewaert, B., Arbustini, E., Mayer, K., Arslan-Kirchner, M.
et al. (2007) Effect of mutation type and location on clinical outcome in
1,013 probands with Marfan syndrome or related phenotypes and FBN1
mutations: an international study. Am. J. Hum. Genet., 81, 454–466.
11. Margraf, R.L., Crockett, D.K., Krautscheid, P.M., Seamons, R., Calderon,
F.R., Wittwer, C.T. and Mao, R. (2009) Multiple endocrine neoplasia type
2 RET protooncogene database: repository of MEN2-associated RET
sequence variation and reference for genotype/phenotype correlations.
Hum. Mutat., 30, 548–556.
12. Lips, C.J., Dreijerink, K.M. and Hoppener, J.W. (2012) Variable clinical
expression in patients with a germline MEN1 disease gene mutation: clues
to a genotype-phenotype correlation. Clinics, 67, 49–56.
13. Marini, F., Falchetti, A., Luzi, E., Tonelli, F. and Maria Luisa, B. (2009)
Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome. Cancer
Syndromes. Bethesda, MD, National Center for Biotechnology
Information (US).











14. Taal, B.G. and Visser, O. (2004) Epidemiology of neuroendocrine
tumours. Neuroendocrinology, 80, 3–7.
15. Tonelli, F., Giudici, F., Fratini, G. and Brandi, M.L. (0000) Pancreatic
endocrine tumors in multiple endocrine neoplasia type 1 syndrome:
review of literature. Endocr. Pract., 17, 33–40.
16. Goudet, P., Murat, A., Binquet, C., Cardot-Bauters, C., Costa, A.,
Ruszniewski, P., Niccoli, P., Menegaux, F., Chabrier, G., Borson-Chazot,
F. et al. (2010) Risk factors and causes of death in MEN1 disease. A GTE
(Groupe d’Etude des Tumeurs Endocrines) cohort study among 758
patients. World J. Surg., 34, 249–255.
17. Levy-Bohbot, N., Merle, C., Goudet, P., Delemer, B., Calender, A., Jolly,
D., Thiefin, G. and Cadiot, G. (2004) Prevalence, characteristics and
prognosis of MEN 1-associated glucagonomas, VIPomas, and
somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines)
registry. Gastroenterol. Clin. Biol., 28, 1075–1081.
18. Triponez, F., Dosseh, D., Goudet, P., Cougard, P., Bauters, C., Murat, A.,
Cadiot, G., Niccoli-Sire, P., Chayvialle, J.A., Calender, A. et al. (2006)
Epidemiology data on 108 MEN 1 patients from the GTE with isolated
nonfunctioning tumors of the pancreas. Ann. Surg., 243, 265–272.
19. Verges, B., Boureille, F., Goudet, P., Murat, A., Beckers, A., Sassolas, G.,
Cougard, P., Chambe, B., Montvernay, C. and Calender, A. (2002)
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium
MEN1 multicenter study. J. Clin. Endocrinol. Metab., 87, 457–465.
20. Goudet, P., Murat, A., Cardot-Bauters, C., Emy, P., Baudin, E., du
Boullay Choplin, H., Chapuis, Y., Kraimps, J.L., Sadoul, J.L., Tabarin, A.
et al. (2009) Thymic neuroendocrine tumors in multiple endocrine
neoplasia type 1: a comparative study on 21 cases among a series of 761
MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J. Surg.,
33, 1197–1207.
21. Goudet, P., Bonithon-Kopp, C., Murat, A., Ruszniewski, P., Niccoli, P.,
Menegaux, F., Chabrier, G., Borson-Chazot, F., Tabarin, A., Bouchard, P.
et al. (0000) Gender-related differences in MEN1 lesion occurrence and
diagnosis: a cohort study of 734 cases from the Groupe d’etude des
Tumeurs Endocrines. Eur. J. Endocrinol., 165, 97–105.
22. Sakurai, A., Suzuki, S., Kosugi, S., Okamoto, T., Uchino, S., Miya, A.,
Imai, T., Kaji, H., Komoto, I., Miura, D. et al. (0000) Multiple endocrine
neoplasia type 1 in Japan: establishment and analysis of a multicentre
database. Clin. Endocrinol. (Oxf.), 76, 533–539.
23. Machens, A., Schaaf, L., Karges, W., Frank-Raue, K., Bartsch, D.K.,
Rothmund, M., Schneyer, U., Goretzki, P., Raue, F. and Dralle, H. (2007)
Age-related penetrance of endocrine tumours in multiple endocrine
neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin.
Endocrinol. (Oxf.), 67, 613–622.
24. Agarwal, S.K., Guru, S.C., Heppner, C., Erdos, M.R., Collins, R.M., Park,
S.Y., Saggar, S., Chandrasekharappa, S.C., Collins, F.S., Spiegel, A.M.
et al. (1999) Menin interacts with the AP1 transcription factor JunD and
represses JunD-activated transcription. Cell, 96, 143–152.
25. Agarwal, S.K., Kennedy, P.A., Scacheri, P.C., Novotny, E.A., Hickman,
A.B., Cerrato, A., Rice, T.S., Moore, J.B., Rao, S., Ji, Y. et al. (2005)
Menin molecular interactions: insights into normal functions and
tumorigenesis. Horm. Metab. Res., 37, 369–374.
26. Agarwal, S.K., Novotny, E.A., Crabtree, J.S., Weitzman, J.B., Yaniv, M.,
Burns, A.L., Chandrasekharappa, S.C., Collins, F.S., Spiegel, A.M. and
Marx, S.J. (2003) Transcription factor JunD, deprived of menin, switches
from growth suppressor to growth promoter. Proc. Natl. Acad. Sci. USA,
100, 10770–10775.
27. Knapp, J.I., Heppner, C., Hickman, A.B., Burns, A.L.,
Chandrasekharappa, S.C., Collins, F.S., Marx, S.J., Spiegel, A.M. and
Agarwal, S.K. (2000) Identification and characterization of JunD missense
mutants that lack menin binding. Oncogene, 19, 4706–4712.
28. Shimazu, S., Nagamura, Y., Yaguchi, H., Ohkura, N. and Tsukada, T.
(2011) Correlation of mutant menin stability with clinical expression of
multiple endocrine neoplasia type 1 and its incomplete forms. Cancer Sci.,
102, 2097–2102.
29. Goudet, P., Cougard, P., Verges, B., Murat, A., Carnaille, B., Calender,
A., Faivre, J. and Proye, C. (2001) Hyperparathyroidism in multiple
endocrine neoplasia type I: surgical trends and results of a 256-patient
series from Groupe D’etude des Neoplasies Endocriniennes Multiples
Study Group. World J. Surg., 25, 886–890.
30. Giraud, S., Zhang, C.X., Serova-Sinilnikova, O., Wautot, V., Salandre, J.,
Buisson, N., Waterlot, C., Bauters, C., Porchet, N., Aubert, J.P. et al.
(1998) Germ-line mutation analysis in patients with multiple endocrine
neoplasia type 1 and related disorders. Am. J. Hum. Genet., 63, 455–467.
31. Calender, A. (2010) Multiple endocrine neoplasia: genetic aspects. Bull.
Acad. Natl. Med., 194, 81–95.
32. Gatta-Cherifi, B., Chabre, O., Murat, A., Niccoli, P., Cardot-Bauters, C.,
Rohmer, V., Young, J., Delemer, B., Du Boullay, H., Verger, M.F. et al.
(0000) Adrenal involvement in MEN1. Analysis of 715 cases from the
Groupe d’etude des Tumeurs Endocrines database. Eur. J. Endocrinol.,
166, 269–279.
33. Triponez, F., Goudet, P., Dosseh, D., Cougard, P., Bauters, C., Murat, A.,
Cadiot, G., Niccoli-Sire, P., Calender, A. and Proye, C.A. (2006) Is
surgery beneficial for MEN1 patients with small (, or ¼ 2 cm),
nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65
patients from the GTE. World J. Surg., 30, 654–662.
34. Green, G.H. and Diggle, P.J. (2007) On the operational characteristics of
the Benjamini and Hochberg false discovery rate procedure. Stat. Appl.
Genet. Mol. Biol., 6, 27.
35. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. and Golani, I. (2001)
Controlling the false discovery rate in behavior genetics research. Behav.
Brain Res., 125, 279–284.
36. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery
rate – a practical and powerful approach to multiple testing. J. R. Stat.
Soc. Ser. B Methodol., 57, 289–300.
37. Teh, B.T. (1998) Thymic carcinoids in multiple endocrine neoplasia type
1. J. Intern. Med., 243, 501–504.
38. Huang, J., Gurung, B., Wan, B., Matkar, S., Veniaminova, N.A., Wan, K.,
Merchant, J.L., Hua, X. and Lei, M. (2012) The same pocket in menin
binds both MLL and JUND but has opposite effects on transcription.
Nature, 482, 542–546.
39. Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A.G., Sorenson, R.J.,
Showalter, H.D., Murai, M.J., Belcher, A.M., Hartley, T. et al. (0000)
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins
in leukemia. Nat. Chem. Biol., 8, 277–284.
40. Zerbini, L.F., de Vasconcellos, J.F., Czibere, A., Wang, Y., Paccez, J.D.,
Gu, X., Zhou, J.R. and Libermann, T.A. (2011) JunD-mediated repression
of GADD45alpha and gamma regulates escape from cell death in prostate
cancer. Cell Cycle, 10, 2583–2591.
41. Chen, D., Reierstad, S., Fang, F. and Bulun, S.E. (2011) JunD and JunB
integrate prostaglandin E2 activation of breast cancer-associated proximal
aromatase promoters. Mol. Endocrinol., 25, 767–775.
42. Dreijerink, K.M., Hoppener, J.W., Timmers, H.M. and Lips, C.J. (2006)
Mechanisms of disease: multiple endocrine neoplasia type 1-relation to
chromatin modifications and transcription regulation. Nature clinical
practice. Endocr. Metab., 2, 562–570.
43. Mensah-Osman, E.J., Veniaminova, N.A. and Merchant, J.L. (2011)
Menin and JunD regulate gastrin gene expression through proximal DNA
elements. Am. J. Physiol. Gastrointest. Liver Physiol., 301, 783–790.
44. Wuescher, L., Angevine, K., Hinds, T., Ramakrishnan, S., Najjar, S.M.
and Mensah-Osman, E.J. (2011) Insulin regulates menin expression,
cytoplasmic localization, and interaction with FOXO1. American journal
of physiology. Endocr. Metab., 301, 474–483.
45. Albert, I. and Jais, J.P. (2000) The use of frailty models in genetic studies:
application to the relationship between end-stage renal failure and
mutation type in Alport syndrome. European Community Alport
Syndrome Concerted Action Group (ECASCA). J. Epidemiol. Biostat. 5,
169–175.
46. Storey, J.D. (2002) A direct approach for false discovery rates. J. R. Stat.
Soc., 64, 479–488.
Human Molecular Genetics, 2013 9
 at IN
SERM
 on A
pril 15, 2013
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
